Safety and Feasibility of Esophagectomy Following Neoadjuvant Immunotherapy Combined with Chemotherapy for Esophageal Squamous Cell Carcinoma.

Autor:	Gu YM; Department of Thoracic Surgery, West China Hospital of Sichuan University, Chengdu, China., Shang QX; Department of Thoracic Surgery, West China Hospital of Sichuan University, Chengdu, China., Zhang HL; Department of Thoracic Surgery, West China Hospital of Sichuan University, Chengdu, China., Yang YS; Department of Thoracic Surgery, West China Hospital of Sichuan University, Chengdu, China., Wang WP; Department of Thoracic Surgery, West China Hospital of Sichuan University, Chengdu, China., Yuan Y; Department of Thoracic Surgery, West China Hospital of Sichuan University, Chengdu, China., Hu Y; Department of Thoracic Surgery, West China Hospital of Sichuan University, Chengdu, China., Che GW; Department of Thoracic Surgery, West China Hospital of Sichuan University, Chengdu, China., Chen LQ; Department of Thoracic Surgery, West China Hospital of Sichuan University, Chengdu, China.
Jazyk:	angličtina
Zdroj:	Frontiers in surgery [Front Surg] 2022 May 26; Vol. 9, pp. 851745. Date of Electronic Publication: 2022 May 26 (Print Publication: 2022).
DOI:	10.3389/fsurg.2022.851745
Abstrakt:	Background: This study aimed to investigate the safety and feasibility of esophagectomy after neoadjuvant immunotherapy and chemotherapy for esophageal squamous cell carcinoma. Methods: We retrospectively identified patients who received neoadjuvant immunotherapy combined with chemotherapy ( n  = 38) in our center between 2020 and 2021. The primary end point was the risk of major complications (grade ≥3) according to the Clavien-Dindo classification. Secondary end points were surgical details, 30-day mortality, and 30-day readministration. Results: The most commonly used regimens of immunotherapy were camrelizumab (36.8%), pembrolizumab (31.5%), tislelizumab (15.8%), sintilimab (13.2%), and toripalimab (2.6%). The median interval to surgery was 63 days (range, 40-147). Esophagectomy was performed in 37 of 38 patients who received neoadjuvant immunotherapy and chemotherapy. All procedures were performed minimally invasively, except for 1 patient who was converted to thoracotomy. Of 37 surgical patients, R0 resection was achieved in 36 patients (97.3%). Pathologic complete response was observed in 9 patients (24.3%). Tumor regression grade I was identified in 17 patients (45.9%). Morbidity occurred in 12 of 37 patients (32.4%). The most common complication was pneumonia (16.2%). There were no deaths or readministration within 30 days. Conclusions: Esophagectomy following neoadjuvant immune checkpoint inhibitor plus chemotherapy for patients with resectable esophageal squamous cell carcinoma appears to be safe and feasible, with acceptable complication rates. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Gu, Shang, Zhang, Yang, Wang, Yuan, Hu, Che and Chen.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu